<DOC>
	<DOCNO>NCT02305563</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness ulocuplumab combination low dose cytarabine treatment Newly Diagnosed Acute Myeloid Leukemia ( AML ) .</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study Ulocuplumab Combination With Low Dose Cytarabine Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Newly Diagnosed Acute Myeloid Leukemia ( AML ) Considered inappropriate intensive remission induction therapy investigator Not eligible stem cell transplantation Acute promyelocytic leukemia Current Myelodysplastic syndrome subject Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>